Last reviewed · How we verify
PCSK9 inhibitor
PCSK9 inhibitor is a Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University. It is currently FDA-approved. Also known as: Evolocumab, Alirocumab, any other PCSK9 inhibitors, Repatha.
At a glance
| Generic name | PCSK9 inhibitor |
|---|---|
| Also known as | Evolocumab, Alirocumab, any other PCSK9 inhibitors, Repatha, Evolocumab (Repatha) |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) (PHASE3)
- Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (EARLY_PHASE1)
- A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) (PHASE2, PHASE3)
- Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma (PHASE2)
- PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke (PHASE4)
- PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer (PHASE2)
- Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events (PHASE3)
- TOP 2301: Neoadjuvant Chemo for NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PCSK9 inhibitor CI brief — competitive landscape report
- PCSK9 inhibitor updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI
Frequently asked questions about PCSK9 inhibitor
What is PCSK9 inhibitor?
PCSK9 inhibitor is a Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University.
Who makes PCSK9 inhibitor?
PCSK9 inhibitor is developed and marketed by The First Affiliated Hospital with Nanjing Medical University (see full The First Affiliated Hospital with Nanjing Medical University pipeline at /company/the-first-affiliated-hospital-with-nanjing-medical-university).
Is PCSK9 inhibitor also known as anything else?
PCSK9 inhibitor is also known as Evolocumab, Alirocumab, any other PCSK9 inhibitors, Repatha, Evolocumab (Repatha).
What development phase is PCSK9 inhibitor in?
PCSK9 inhibitor is FDA-approved (marketed).
Related
- Manufacturer: The First Affiliated Hospital with Nanjing Medical University — full pipeline
- Also known as: Evolocumab, Alirocumab, any other PCSK9 inhibitors, Repatha, Evolocumab (Repatha)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing